In order for our site to display correctly you will need a newer version of your web browser.
The following browsers support numerous web standards including CSS,XHTML, and the DOM (a universal means of controlling the behavior of web pages):
- Netscape v7 or higher (all platforms), Mozilla FireFox (Windows), Camino (Mac OS X), Galeon (Linux GNOME Desktop) or other browser stemming from the Mozilla.org project.
- Opera v7 or higher (Windows, Linux)
- Apple's Safari (Mac OS X)
- Konqueror (Linux KDE Desktop)
- Microsoft Internet Explorer v6 or higher (Windows) or v5 or higher (Macintosh)
Please note that this is not intended be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Finding Cures. Saving Children.
Charles J. Russell, PhD
Assistant Member, St. Jude Faculty
Departments
Infectious Diseases
Divisions
Virology
Contact Information
Charles Russell, PhD
Infectious Diseases
MS 330, Room I-6309
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: charles.russell@stjude.org
Phone: (901) 595-5648
FAX: (901) 595-8559
Education
PhD - University of California at Berkeley
Research Interests
- Molecular mechanisms of infectious diseases caused by emerging influenza viruses and paramyxoviruses
- Negative-strand RNA virus replication and pathogenesis, focusing on influenza viruses and paramyxoviruses
- Viral envelope glycoproteins as targets for novel vaccines and drugs
Selected Publications
Reed ML, Yen H-L, DuBois RM, Bridges OA, Salomon R, Webster RG, Russell CJ. Amino acid residues in the fusion peptide pocket regulate the pH of activation of the H5N1 influenza virus hemagglutinin (HA) protein. J Virol 83:3568-3580, 2009.
Jones B, Zhan X, Mishin V, Slobod KS, Surman S, Russell CJ, Portner A, Hurwitz JL. Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine 27:1848-1857, 2009.
Zhan X, Slobod KS, Krishnamurthy S, Luque LE, Takimoto T, Jones B, Surman S, Russell CJ, Portner A, Hurwitz JL. Sendai virus recombinant vaccine expressing hPIV-3 HN or F elicits protective immunity and combines with a second recombinant to prevent hPIV-1, hPIV-3 and RSV infections. Vaccine 26:3480-3488, 2008.
Luque LE, Russell CJ. Spring-loaded heptad repeat residues regulate the expression and activation of the paramyxovirus fusion (F) protein. J Virol 81:3130-3141, 2007.
Ilyushina NA, Govorkova EA, Russell CJ, Hoffman E, Webster RG. Contribution of H7 hemagglutinin to anantadine resistance and infectivity of influenza virus. J Gen Virol 88:1266-1274, 2007.
Russell CJ, Luque LE. The structural basis of paramyxovirus invasion. Trends Microbiol 14:243-246, 2006.
Russell CJ, Webster RG. The genesis of a pandemic influenza virus. Cell 123:368-371, 2005.
Russell CJ, Jardetzky TS, Lamb RA. Conserved glycine residues in the fusion peptide of the paramyxovirus fusion protein regulate activation of the native state. J Virol 78:13727-13742, 2004.
Waning DL, Russell CJ, Jardetzky TS, Lamb RA. Activation of a paramyxovirus fusion protein is modulated by inside-out signaling from the cytoplasmic tail. Proc Natl Acad Sci USA 101:9217-9222, 2004.
Russell CJ, Kantor KL, Jardetzky TS, Lamb RA. A dual-functional paramyxovirus F protein regulatory switch segment: activation and membrane fusion. J Cell Biol 163:363-374, 2003.
Takeda M, Leser GP, Russell CJ, Lamb RA. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc Natl Acad Sci USA 100:14610-14617, 2003.
Russell CJ, Jardetzky TS, Lamb RA. Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO Journal 20:4024-4034, 2001.
Last update: June 2009
